Logo

American Heart Association

  45
  0


Final ID: MP861

Impact of Sodium Glucose Cotransporter 2-Inhibitors in Valvular Heart Disease

Abstract Body (Do not enter title and authors here): Introduction:
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown cardiovascular benefits in randomized trials, including reductions in mortality and heart failure hospitalizations. However, real-world evidence on their effectiveness across the population with valvular heart disease (VHD) remains limited.

Methods:
We analyzed two matched cohorts from a federated health research network. We identified all the population VHD (excluding those who have received valve replacement or repair, those with congenital heart disease, and those with systolic heart failure). Then we divided them into those with SGLT2i prescription (n = 107,607) and those without (n = 107,607). Propensity score matching was performed on 38 variables encompassing demographics, comorbidities, medications, and laboratory covariates. Outcomes were assessed between 30 and 365 days post-index SGLT2i prescription, and those with outcomes prior to the analysis were excluded. Risk estimates, Kaplan-Meier survival analysis, and hazard ratios (HR) with 95% confidence intervals (CI) were calculated.

Results:
SGLT2i use was associated with a significantly lower risk of all-cause mortality (2.8% vs. 5.7%; HR: 0.433, 95% CI: 0.414–0.452; p<0.001). Survival at one year was higher in the SGLT2i group (96.93% vs. 93.12%). No significant differences were observed for atrial fibrillation (4.3% vs. 3.6%; HR: 1.014, 95% CI: 0.965–1.065; p=0.586) or ED visits (7.5% vs. 6.3%; HR: 1.036, 95% CI: 0.992–1.083; p=0.111). Rates of hospital admissions (0.01% vs. 0.01%; HR: 2.638, 95% CI: 0.714–9.746; p=0.459), ICU admissions (0.09% vs. 0.10%; HR: 0.845, 95% CI: 0.640–1.117; p=0.415), and cardiogenic shock (0.20% vs. 0.21%; HR: 0.836, 95% CI: 0.693–1.009; p=0.08) were similar between groups.

Conclusion:
Among the population with VHD, SGLT2i use was associated with a 57% relative reduction in all-cause mortality. Other outcomes, including atrial fibrillation, ED visits, ICU admissions, and cardiogenic shock, showed no significant differences. These findings support the need for further research.
  • Evbayekha, Endurance  ( St. Lukes Hospital , Chesterfield , Missouri , United States )
  • Cumaaran, Christina  ( American international school of medicine , Georgetown , Guyana )
  • Dahata, Niharika  ( American international school of medicine , Georgetown , Guyana )
  • Ozojide, Kingsley  ( Nottingham Trent University , Nottingham , United Kingdom )
  • Akpamgbo, Emmanuel  ( St. Lukes Hospital , Chesterfield , Missouri , United States )
  • Okobi, Okelue  ( St. Lukes Hospital , Chesterfield , Missouri , United States )
  • Author Disclosures:
    Endurance Evbayekha: DO NOT have relevant financial relationships | Christina Cumaaran: No Answer | Niharika Dahata: DO NOT have relevant financial relationships | Kingsley Ozojide: DO NOT have relevant financial relationships | Emmanuel Akpamgbo: DO NOT have relevant financial relationships | Okelue Okobi: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:
More abstracts on this topic:
C-C Chemokine Receptor Type 2 and Matrix Metalloproteinases Molecular Interaction in Rat Abdominal Aortic Aneurysm

Zaghloul Mohamed, Elizondo Benedetto Santiago, Arif Batool, Heo Gyu Seong, Luehmann Hannah, Liu Yongjian, Gropler Robert, Sadeghi Mehran, Zayed Mohamed

Acceptability and Gain of Knowledge of Community Educational Tools About Rheumatic Heart Disease Integrated With Screening In Low-Income Settings

Abrams Jessica, Nunes Maria, Diniz Marina, Fraga Lucas, Paula Luiza, Coelho Cecilia, Tacuri Chavez Luz Marina, Lemos Larissa, Correia Julliane, Ribeiro Antonio, Nascimento Bruno, Sable Craig, Spaziani Alison, Zuhlke Liesl, Cardoso Clareci, Vinhal Wanessa, Ribeiro Isabely, Oliveira Kaciane, Amaral Ingred Beatriz

More abstracts from these authors:
Glucagon Receptor Agonist Impact on Cardiac Amyloidosis. A Retrospective Propensity Matched Analysis

Okorigba Efeturi, Eziyi Ure, Oghotuoma Oghenemaro, Nwatamole Bright, Okobi Okelue, Ubajaka Chioma, Evbayekha Endurance

SGLT2 Inhibitors in Rheumatic Heart Disease

Oparah Miracle, Evbayekha Endurance

You have to be authorized to contact abstract author. Please, Login
Not Available